Novel Insights into Molecular Mechanisms and Therapy of Oral Cancer

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Pathology".

Deadline for manuscript submissions: closed (30 November 2024) | Viewed by 1770

Special Issue Editor


E-Mail Website
Guest Editor
Department of Oral Medicine and Diagnostic Science, College of Dentistry, University of Illinois at Chicago, Chicago, IL 60612, USA
Interests: oral microbiome; immunotherapy; oral inflammatory axes

Special Issue Information

Dear Colleagues,

It is increasingly evident that the continually significant death rates for Black men compared to other males for oral squamous cell carcinoma (OSCC) and head and neck carcinoma (HNSCC) include important molecular biology roles that impact treatment outcomes. Furthermore, a discussion on molecular biologic relationships is needed to better understand how to implement early detection, screening, treatment, and outcomes for OSCC and HNSCC. Studies and reviews in this Special Issue will address recent technological and treatment developments, amplifying our understanding of how oral molecular biology affects cancer control and treatment. We hope to foster a multidisciplinary view of molecular biology oral microbial and host cellular roles while incorporating microbiology–virology, biochemistry, mucosal immunology, cell biology and pathology, and other technological sciences. This Special Issue will address this relationship, enhancing the opportunity to develop avenues to reduce racial disparity and death rates from these cancers.

Dr. Joel L. Schwartz
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • microbiome
  • metabolomics
  • genomics
  • transcriptomics
  • proteomics
  • immunotherapy
  • immune detection
  • single-cell screening
  • oncogenesis
  • carcinogenesis

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

12 pages, 3840 KiB  
Systematic Review
Prognostic Significance of Tumor–Stroma Ratio (TSR) in Head and Neck Squamous Cell Carcinoma: Systematic Review and Meta-Analysis
by Ilaria Girolami, Domenico Damiani, Rosa Negro, Monir Abousiam, Luca Gazzini, Luca Calabrese and Esther Hanspeter
Cells 2024, 13(21), 1772; https://doi.org/10.3390/cells13211772 - 26 Oct 2024
Cited by 1 | Viewed by 1375
Abstract
The management of head and neck squamous cell carcinoma (HNSCC) relies heavily on TNM staging and WHO histologic grading; however, in recent years, the analysis of prognostic markers expressed in the tumor stroma has gained attention. The tumor–stroma ratio (TSR) quantifies the proportion [...] Read more.
The management of head and neck squamous cell carcinoma (HNSCC) relies heavily on TNM staging and WHO histologic grading; however, in recent years, the analysis of prognostic markers expressed in the tumor stroma has gained attention. The tumor–stroma ratio (TSR) quantifies the proportion of tumor tissue relative to the surrounding stromal tissue; it is assessed with the percentage of stromal tissue within the tumor area, with a cutoff point of 50% being widely used to discriminate high-stroma cancer. In this systematic review and meta-analysis, we investigated the potential prognostic role of the TSR in HNSCC. After a literature screening, 24 studies dealing with the TSR and survival outcomes were included. The TSR showed a significant association with overall survival (OS) in both unadjusted and adjusted measures (RR 2.04, CI 1.57–2.65, p < 0.01; HR 2.36 CI 1.89–2.94, p < 0.00001), with an even stronger prognostic potential in oral cavity/oral tongue cancers (RR 2.44 CI 1.84–3.22, p < 0.00001). The TSR also showed prognostic value when dealing with cancer-specific survival and was associated with a reduction in disease-free survival (DFS). In particular, the TSR also retained its prognostic role in terms of DFS when specifically considering early-stage cancers in both unadjusted and adjusted analyses (RR 1.81 CI 1.57–2.10, p < 0.00001; HR 2.09 CI 1.58–2.76, p < 0.00001). Therefore, we conclude that the TSR is a reliable prognostic marker that is easy to assess in routine histological slides and can be effectively implemented in the routine evaluation of HNSCC. Full article
(This article belongs to the Special Issue Novel Insights into Molecular Mechanisms and Therapy of Oral Cancer)
Show Figures

Figure 1

Back to TopTop